Atopic dermatitis (AD) is one of the most common chronic skin diseases and is characterised by itch and inflammatory eczematous lesions. The disease causes a wide spectrum of adverse impacts on the patients and their families, as well as the entire society. Although many effective therapies have been developed for controlling AD symptoms, there is a substantial proportion of AD patient exhibits suboptimal treatment outcomes.
In a recent interview with Dr. Lai Yik Kiu Dominic, Specialist in Dermatology and Venereology, the disease burden of AD and current unmet needs in managing the disease are highlighted. In particular, the contributing factors for the occurrence of difficult-to-treat AD are discussed. Besides, the clinical value of biomarkers in AD diagnosis is reviewed in the Epoch section. AD patients face multi-dimensional impacts during the current COVID-19 pandemic, such as increased risk of infection and psychological distress. Hence, clinical issues including vaccination and immunosuppressive therapy in AD patients are evaluated in this issue.
Besides AD, clinical opinions in management of relapse/refractory multiple myeloma (RRMM) will be featured in the Industry Updates section. On the other hand, the association between coffee consumption and the onset of osteoporosis, the potential application of contact lens as ocular drug carrier, and the impact of nutritional intervention are discussed in the Epoch section.
In the 5th wave of COVID-19 pandemic, our healthcare system is at the edge of collapse and the frontline healthcare professionals are facing huge pressure and difficulty. We would like to take this opportunity to thank and appreciate all the efforts from clinicians as well as allied workers in fighting the current pandemic.
Best wishes, stay safe and healthy!
Dr. Roy Yuen-chi Lau
PhD, DBA, FRSPH, MIET, MRSC, MSB, CBiol, CSci
In order to provide articles better matched with your interest, a V∙Pulse Reader Survey has been launched to collect your opinions on the preferred topics. Please provide your opinions by completing the online questionnaire in the link here.